Ad Code: Imbruvica - eBook Display Banners Conference - CPE - 103028

Researchers evaluated whether targeted next-generation sequencing was comparable to fluorescence in situ hybridization for detecting genetic alterations in CLL.

Adding BCR kinase inhibitor ibrutinib or idelalisib to monoclonal antibody pembrolizumab increases treatment efficacy in CLL with Richter transformation.

Researchers at the 2024 ASCO Annual Meeting studied the rapid titration of venetoclax for chronic lymphocytic leukemia and mantle cell lymphoma.

AI and ML advances chronic lymphocytic leukemia therapies.

The following is a summary of “Association between treatment (tx) response and PFS and OS in R/R...

The following is a summary of “Evaluating CR as a surrogate endpoint for PFS in R/R chronic...

Fixed duration ibrutinib plus venetoclax benefited survival outcomes in patients with high-risk CLL/SLL over more than 5 years of follow-up.

ASCO Voices has become an anticipated staple of the conference. It is an opportunity for physicians to share their platform and experiences on a scale unlike any other.

Are you traveling to Chicago for ASCO? Here’s some places to visit.

What ASCO ancillary event are you excited to attend?

The Industry Expert Theater offers hour-long, nonaccredited educational presentations by industry leaders. These sessions will cover the latest advancements in oncology practices, products, services, and technologies.